115 related articles for article (PubMed ID: 1673628)
1. Lactation inhibition by the dopamine agonist CV 205-502.
van der Heijden PF; Kremer JA; Brownell J; Rolland R
Br J Obstet Gynaecol; 1991 Mar; 98(3):270-6. PubMed ID: 1673628
[TBL] [Abstract][Full Text] [Related]
2. Postpartum return of pituitary and ovarian activity during lactation inhibition with the new dopamine agonist CV 205-502 and during normal lactation.
Kremer JA; van der Heijden PF; Schellekens LA; Thomas CM; Brownell J; Rolland R
Acta Endocrinol (Copenh); 1990 Jun; 122(6):759-65. PubMed ID: 1973867
[TBL] [Abstract][Full Text] [Related]
3. Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. European Multicentre Study Group for Cabergoline in Lactation Inhibition.
BMJ; 1991 Jun; 302(6789):1367-71. PubMed ID: 1676318
[TBL] [Abstract][Full Text] [Related]
4. Bromocriptine compared to long-acting estrogens in lactation prevention: clinical efficacy, prolactin secretion and coagulation parameters.
Leleux D; Merveille JJ; Capel P; Picard C; L'Hermite M
Eur J Obstet Gynecol Reprod Biol; 1981 Oct; 12(4):235-42. PubMed ID: 7197648
[TBL] [Abstract][Full Text] [Related]
5. Lactation inhibition by a single injection of a new depot-bromocriptine.
Kremer JA; Rolland R; van der Heijden PF; Schellekens LA; Vosmar MB; Lancranjan I
Br J Obstet Gynaecol; 1990 Jun; 97(6):527-32. PubMed ID: 2378830
[TBL] [Abstract][Full Text] [Related]
6. CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia.
van der Heijden PF; de Wit W; Brownell J; Schoemaker J; Rolland R
Eur J Obstet Gynecol Reprod Biol; 1991 Jul; 40(2):111-8. PubMed ID: 1676973
[TBL] [Abstract][Full Text] [Related]
7. Effect of CV 205-502 in hyperprolactinaemic patients intolerant of bromocriptine.
Newman CB; Hurley AM; Kleinberg DL
Clin Endocrinol (Oxf); 1989 Oct; 31(4):391-400. PubMed ID: 2576397
[TBL] [Abstract][Full Text] [Related]
8. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia.
Homburg R; West C; Brownell J; Jacobs HS
Clin Endocrinol (Oxf); 1990 May; 32(5):565-71. PubMed ID: 1973085
[TBL] [Abstract][Full Text] [Related]
9. Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205-502.
van't Verlaat JW; Croughs RJ; Brownell J
Clin Endocrinol (Oxf); 1990 Nov; 33(5):619-24. PubMed ID: 1979262
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of puerperal lactation with 2-mercaptopropionyl-glycine.
Akrivis C; Vezyraki P; Kiortsis DN; Fotopoulos A; Evangelou A
Eur J Clin Pharmacol; 2000 Dec; 56(9-10):621-3. PubMed ID: 11214766
[TBL] [Abstract][Full Text] [Related]
11. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
Rains CP; Bryson HM; Fitton A
Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of the dopamine agonists quinagolide (CV 205-502) and bromocriptine on prolactin secretion and growth of SMtTW pituitary tumors in the rat.
Trouillas J; Chevallier P; Claustrat B; Hooghe-Peters E; Dubray C; Rousset B; Girod C
Endocrinology; 1994 Jan; 134(1):401-10. PubMed ID: 7903933
[TBL] [Abstract][Full Text] [Related]
13. Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study.
Verhelst JA; Froud AL; Touzel R; Wass JA; Besser GM; Grossman AB
Acta Endocrinol (Copenh); 1991 Oct; 125(4):385-91. PubMed ID: 1683503
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of puerperal lactation: evaluation of bromocriptine and placebo.
Bhardwaj N
Aust N Z J Obstet Gynaecol; 1979 Aug; 19(3):154-7. PubMed ID: 391210
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of puerperal lactation. A double blind study of bromocriptine and placebo.
Dewhurst CJ; Harrison RF; Biswas S
Acta Obstet Gynecol Scand; 1977; 56(4):327-31. PubMed ID: 341635
[TBL] [Abstract][Full Text] [Related]
16. Lactation suppression with bromocriptine.
Hutchison P; Sill H
N Z Med J; 1981 Oct; 94(694):309-10. PubMed ID: 7033847
[TBL] [Abstract][Full Text] [Related]
17. Oral cabergoline. Single-dose inhibition of puerperal lactation.
Caballero-Gordo A; Lopez-Nazareno N; Calderay M; Caballero JL; Mancheño E; Sghedoni D
J Reprod Med; 1991 Oct; 36(10):717-21. PubMed ID: 1683403
[TBL] [Abstract][Full Text] [Related]
18. [Puerperal inhibition of lactation with metergoline or bromocriptine].
Fischer T; Streitmatter A; Gerede A; Frauendorf A; Krause M; Feige A
Z Geburtshilfe Neonatol; 1995; 199(3):111-5. PubMed ID: 7553254
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of lactation by a long-acting bromocriptine.
Peters F; Del Pozo E; Conti A; Breckwoldt M
Obstet Gynecol; 1986 Jan; 67(1):82-5. PubMed ID: 3940343
[TBL] [Abstract][Full Text] [Related]
20. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
Brue T; Pellegrini I; Gunz G; Morange I; Dewailly D; Brownell J; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 1992 Mar; 74(3):577-84. PubMed ID: 1346788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
